A second‐generation CD38‐CAR‐T cell for the treatment of multiple myeloma

A second‐generation CD38‐CAR‐T cell for the treatment of multiple myeloma

Abstract Background Multiple myeloma (MM) is an aggressive plasma cell malignancy, causing a number of deaths worldwide every year. Chimeric antigen receptor (CAR) transduced T‐cell therapy has been a promising immunotherapy against hematological malignancies. Methods In this study, we developed a s...

Full description

Bibliographic Details
Main Authors: Hongwen Li, Jing Li, Jiazhuo Wu, Zhuangzhuang Shi, Yuyang Gao, Wenting Song, Jiwei Li, Zhaoming Li, Mingzhi Zhang
Format: Article
Language:English
Published: Wiley 2023-05-01
Series:Cancer Medicine
Subjects:
CD38
chimeric antigen receptor
immunotherapy
multiple myeloma
Online Access:https://doi.org/10.1002/cam4.5818

Internet

https://doi.org/10.1002/cam4.5818

Similar Items